Breast Cancer Clinical Trial
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
Summary
The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists
Eligibility Criteria
Inclusion Criteria:
Advanced breast cancer with positive BRCA1 or BRCA2 status
Failed at least one prior chemotherapy
In investigators opinion, no curative standard therapy exists
Measurable disease
Exclusion Criteria:
Brain metastases
Less than 28 days since last treatment used to treat the disease
Considered a poor medical risk due to a serious uncontrolled disorder
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
West Hollywood California, 90048, United States
Boston Massachusetts, 02115, United States
Melbourne , 3000, Australia
Randwick , 2031, Australia
Duarte CA, 91010, Canada
Kiel , 24105, Germany
Köln , 50937, Germany
München , 81675, Germany
Tel-Aviv , 64239, Israel
Hospitalet deLlobregat , 08907, Spain
Madrid , 08035, Spain
Lund , 221 8, Sweden
Cambridge , CB2 0, United Kingdom
Edinburgh , EH4 2, United Kingdom
Fulham , SW3 6, United Kingdom
London , SE1 9, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?